vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2019-16-1-117-128vestim-483Research ArticleОБЗОРЫREVIEWSРекомендации по ведению пациентов с аксиальным спондилоартритомRecommendations on the management of patients with axial spondyloarthritisКундерЕ. В.KundzerA. V.

Кундер Елена Владимировна – доктор медицинских наук, профессор

ул. П. Бровки, 3/3, 220013, г. Минск

Alena V. Kundzer – D. Sc. (Med.), Professor

3/3, P. Browka Str., 220013, Minsk

elsid7@mail.ruБелорусская медицинская академия последипломного образованияBelarusian Medical Academy of Postgraduate Education201912032019161117128Copyright © Кундер Е.В., 20192019Кундер Е.В.Kundzer A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/483

Спондилоартриты представляют собой группу заболеваний, характеризующихся первично хроническим, прогрессирующим воспалительным процессом с поражением осевого скелета (позвоночника и крестцовоподвздошных сочленений) и периферических суставов, имеющих некоторые общие этиопатогенетические и клинические признаки. Современная концепция спондилоартритов предусматривает выделение преимущественно аксиального и преимущественно периферического вариантов заболевания. Проблема спондилоартритов находится в центре внимания медицинской общественности. Изучению аспектов возникновения и развития заболевания, терапии и профилактики прогрессирования болезни посвящены научные исследования ведущих ревматологических центров. Значительный прогресс достигнут в лечении спондилоартритов. В статье изложены современные рекомендации по ведению пациентов с аксиальным спондилоартритом.

Spondyloarthritis is a group of diseases characterized by a primarily chronic, progressive inflammatory process with the affection of the axial skeleton (spine and sacroiliac joints) and peripheral joints having some common etiopathogenetic and clinical signs. The modern concept of spondyloarthritis involves the isolation of predominantly axial and predominantly peripheral variants of the disease. The problem of spondyloarthritis is in the center of attention of the medical community. Studies of the leading rheumatological centers are devoted to the aspects of the onset and development of the disease, therapy and prevention of disease progression. Signifcant progress has been made in the treatment of spondyloarthritis. The article contains the current recommendations on the management of patients with axial spondylitis.

аксиальный спондилоартритлечениемониторингaxial spondylitistreatmentmonitoringReferences2016 update of ASAS-EULAR recommendations for axial spondyloarthritis / D. van der Heijde [et al.] // Ann. Rheum. Dis. – 2017. – Vol. 76. – P. 978–991. https://doi.org/10.1136/annrheumdis-2016-210770van der Heijde D., Ramiro S., Landewe R., Baraliakos X., Van den Bosch F., Sepriano A. [et al.]. 2016 update of ASASEULAR recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, vol. 76, pp. 978–991. https://doi.org/10.1136/annrheumdis-2016-210770ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF-therapy / N. Vastesaeger [et al.] // Rheumatol. Clin. – 2014. – Vol. 10, N 4. – P. 204–209. https://doi.org/10.1016/j.reumae.2013.12.025Vastesaeger N., Cruyssen B. V., Mulero J., Masmitjá J. G., Zarco P., Almodovar R., Font P., Juanola X., CollantesEstevez E. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF-therapy. Reumatología Clínica, 2014, vol. 10, no. 4, pp. 204–209. https://doi.org/10.1016/j.reumae.2013.12.025The Assessment of SponyloArthritis intrernational Society (ASAS) handbook: a guide to assess spondyloarthritis / J. Sieper [et al.] // Ann. Rheum. Dis. – 2009. – Vol. 68, suppl. 2. – P. ii1–ii44. https://doi.org/10.1136/ard.2008.104018Sieper J., Rudwaleit M., Baraliakos X., Brandt J., Braun J., Burgos-Vargas R. [et al.]. The Assessment of SponyloArthritis intrernational Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases, 2009, vol. 68, suppl. 2, pp. ii1–ii44. https://doi.org/10.1136/ard.2008.104018ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis / D. van der Heijde [et al.] // Ann. Rheum. Dis. – 2008. – Vol. 68, N 12. – P. 1811–1818. https://doi.org/10.1136/ard.2008.100826van der Heijde D., Lie E., Kvien T. K., Sieper J., van den Bosch F., Listing J., Braun J., Landewe R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2008, vol. 68, no. 12, pp. 1811–1818. https://doi.org/10.1136/ard.2008.100826Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort / S. Ramiro [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73, N 8. – P. 1455–1461. https://doi.org/10.1136/annrheumdis-2014-205178Ramiro S., van der Heijde D., van Tubergen A., Stolwijk C., Dougados M., van den Bosch F., Landewé R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Annals of the Rheumatic Diseases, 2014, vol. 73, no. 8, pp. 1455–1461. https://doi.org/10.1136/annrheumdis-2014-205178Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort / V. Navarro-Compan [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 75, N 5. – P. 874–878. https://doi.org/10.1136/annrheumdis-2015-207786Navarro-Compán V., Ramiro S., Landewé R., Dougados M., Miceli-Richard C., Richette P., van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Annals of the Rheumatic Diseases, 2015, vol. 75, no. 5, pp. 874–878. https://doi.org/10.1136/annrheumdis-2015-207786Amor, B. Data management in spondyloarthropathies / B. Amor // Rheumatol. Eur. – 1996. – Vol. 25, N 3. – P. 92–95.Amor B. Data management in spondyloarthropathies. Rheumatology Europe, 1996, vol. 25, no. 3, pp. 92–95.Baseline radiographic damage, elevated acte-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis / D. Poddubnyy [et al.] // Arthritis Rheum. – 2012. – Vol. 64, N 5. – P. 1388–1398. https://doi.org/10.1002/art.33465Poddubnyy D., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J., Rudwaleit M. Baseline radiographic damage, elevated acte-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis & Rheumatology, 2012, vol. 64, no. 5, pp. 1388–1398. https://doi.org/10.1002/art.33465Effcacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 / J. Sieper [et al.] // Ann. Rheum. Dis. – 2013. – Vol. 73, N 1. – P. 101–107. https://doi.org/10.1136/annrheumdis-2012-203201Sieper J., Lenaerts J., Wollenhaupt J., Rudwaleit M., Mazurov V. I., Myasoutova L., Park S., Song Y., Yao R., Chitkara D., Vastesaeger N. Effcacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 101–107. https://doi.org/10.1136/annrheumdis-2012-203201Bakland, G. Increased mortality in ankylosing spondylitis is related to disease activity / G. Bakland, J. T. Gran, J. C. Nossent // Ann. Rheum. Dis. – 2011. – Vol. 70, N 11. – P. 1921–1925. https://doi.org/10.1136/ard.2011.151191Bakland G., Gran J. T., Nossent J. C. Increased mortality in ankylosing spondylitis is related to disease activity. Annals of the Rheumatic Diseases, 2011, vol. 70, no. 11, pp. 1921–1925. https://doi.org/10.1136/ard.2011.151191Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis / F. Kroon [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 71, N 10. – P. 1623–1629. https://doi.org/10.1136/annrheumdis-2012-201370Kroon F., Landewé R., Dougados M., van der Heijde D. Continuous nsaid use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1623–1629. https://doi.org/10.1136/annrheumdis-2012-201370Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort / D. Poddubnyy [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 71, N 10. – P. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252Poddubnyy D., Rudwaleit M., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomized multicenter trial (ENRADAS) / J. Sieper [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 75, N 8. – P. 1438–1443. https://doi.org/10.1136/annrheumdis-2015-207897Poddubnyy D., Rudwaleit M., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from German spondyloarthritis inception cohort. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 10, pp. 1616–1622. https://doi.org/10.1136/annrheumdis-2011-201252Effcacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomized, placeboconrtolled short-term trial / H. Haibel [et al.] // Ann. Rheum. Dis. – 2013. – Vol. 73, N 1. – P. 243–246. https://doi.org/10.1136/annrheumdis-2012-203055Haibel H., Fendler C., Listing J., Callhoff J., Braun J., Sieper J. Effcacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomized, placebo-conrtolled short-term trial. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 243–246. https://doi.org/10.1136/annrheumdis-2012-203055Chen, J. Sulfasalazin for ankylosing spondylitis / J. Chen, C. Liu // Cochrane Database Syst. Rev. – 2006. – Vol. 2. – CD004800.Chen J., Liu C. Sulfasalazin for ankylosing spondylitis. Cochrane Database of Systematic Reviews, 2006, vol. 2, p. CD004800.Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study / S. Arends [et al.] // Arthritis Res. Ther. – 2011. – Vol. 13, N 3. – P. R94. https://doi.org/10.1186/ar3369Arends S., Brouwer E., van der Veer E., Groen H., Leijsma M. K., Houtman P. M., Jansen T. L. Th. A., Kallenberg C. G. M., Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research & Therapy, 2011, vol. 13, no. 3, p. R94. https://doi.org/10.1186/ar3369Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? / A. Sepriano [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 6. – P. 1262–1263. https://doi.org/10.1136/annrheumdis-2015-208964Sepriano A., Rudwaleit M., Sieper J., van den Berg R., Landewé R., van der Heijde D.Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? Annals of the Rheumatic Diseases, 2016, vol. 75, no. 6, pp. 1262–1263. https://doi.org/10.1136/annrheumdis-2015-208964Effcacy and safety of adalimumab in patients with non-radiographic sxisl spondyloarthritis: results of randomised placebо-controlled trial (ABILITY-1) / J. Sieper [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 72, N 6. – P. 815–822. https://doi.org/10.1136/annrheumdis-2012-20176620Sieper J., van der Heijde D., Dougados M., Mease P. J., Maksymowych W. P., Brown M. A., Arora V., Pangan A. L. Effcacy and safety of adalimumab in patients with non-radiographic sxisl spondyloarthritis: results of randomised placebоcontrolled trial (ABILITY-1). Annals of the Rheumatic Diseases, 2012, vol. 72, no. 6, pp. 815–822. https://doi.org/10.1136/annrheumdis-2012-201766A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis / J. Sieper [et al.] // Arthritis Rheumatol. – 2015. – Vol. 67, N 10. – P. 2702– 2712. https://doi.org/10.1002/art.39257Sieper J., van der Heijde D., Dougados M., Maksymowych W. P., Scott B. B., Boice J. A. [et al.]. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis and Rheumatology, 2015, vol. 67, no. 10, pp. 2702–2712. https://doi.org/10.1002/art.39257Effcacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomized placebo-controlled phase 3 study / R. Landewe [et al.] // Ann. Rhum. Dis. – 2013. – Vol. 73, N 1. – P. 39–47. https://doi.org/10.1136/annrheumdis-2013-204231Landewe R., Deodhar J. A., Dougados M., Maksymowych W. P., Mease P. J., Reveille J. D. [et al.]. Effcacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a doubleblind randomized placebo-controlled phase 3 study. Annals of the Rheumatic Diseases, 2013, vol. 73, no. 1, pp. 39–47. https://doi.org/10.1136/annrheumdis-2013-204231First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis / J. Braun [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65, N 3. – P. 316–320. https://doi.org/10.1136/ard.2005.040758Braun J., Davis J., Dougados M., Sieper J., van der Linden S., van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, vol. 65, no. 3, pp. 316–320. https://doi.org/10.1136/ard.2005.040758Ankylosing Spondylitis Disease Activity score (ASDAS): defning cut-off values for disease activity states and improvement scoreas / P. Machado [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 70, N 1. – P. 47–53. https://doi.org/10.1136/ard.2010.138594Machado P., Landewe R., Lie E., Kvien T. K., Braun J., Baker D., van der Heijde D. Ankylosing Spondylitis Disease Activity score (ASDAS): defning cut-off values for disease activity states and improvement scoreas. Annals of the Rheumatic Diseases, 2010, no. 1, vol. 70, pp. 47–53. https://doi.org/10.1136/ard.2010.138594EULAR recommendations for the mahagement of rheumatpod arthritis with synthetic and biological diseasemodifying drugs: 2013 update / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73. – P. 492–509.Smolen J. S., Landewe R., Bijsma J., Burmester G., Chatzidionysiou K., Dougados M. [et al.]. EULAR recommendations for the mahagement of rheumatoid arthritis with synthetic and biological disease-modifying drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, vol. 73, pp. 492–509.Sekukinumab, a human anti-IL A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial / W. Hueber [et al.] // Gut. – 2012. – Vol. 61. – P. 1693–1700.Hueber W., Sands B. E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P. D. [et al.]. Secukinumab in Crohn’s Disease Study Group. Sekukinumab, a human anti-IL A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut, 2012, vol. 61, pp. 1693–1700.Sekukinumab in plaque psoriasis-results of two phase 3 trials / R. G. Langley [et al.] // N. Engl. J. Med. – 2014. – Vol. 371. – P. 326–338.Langley R. G., Elewski B.E., Lebwohl M., Reich K., Griffths C.E., Papp K. [et al.]. ERASURE Study Sekukinumab in plaque psoriasis-results of two phase 3 trials. New England Journal of Medicine, 2014, vol. 371, pp. 326–338.Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial / W. J. Sanborn [et al.] // Gut. – 2007. – Vol. 56, N 9. – P. 1232–1239. https://doi.org/10.1136/gut.2006.106781Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut, 2007, vol. 56, no. 9, pp. 1232–1239. https://doi.org/10.1136/gut.2006.106781Adalimumab signifcantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis / J. C. van Denderen [et al.] // J. Rheumatol. – 2014. – Vol. 41, N 9. – P. 1843–1848. https://doi.org/10.3899/jrheum.131289van Denderen J. C., Visman I. M., Nurmohamed M. T., Suttorp-Schulten M. S. A., van der Horst-Bruinsma I. E. Adalimumab signifcantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. Journal of Rheumatology, 2014, vol. 41, no. 9, pp. 1843–1848. https://doi.org/10.3899/jrheum.131289European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update / L. Gosses [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75. – P. 499–510.Gosses L., Smolen J.S., Ramiro S., de Wit M., Cutolo M., Dougados M. [et al.]. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, vol. 75, pp. 499–510.Effectiveness of switching between TNF inhibitors in ankylosing spondylitis data from the NOR-DMARD register / E. Lie [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 70, N 1. – P. 157–163. https://doi.org/10.1136/ard.2010.131797Lie E., van der Heijde D., Uhlig T., Mikkelsen K., Rodevand E., Koldingsnes W., Kaufmann C., Kvien T. K. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis data from the NOR-DMARD register. Annals of the Rheumatic Diseases, 2010, vol. 70, no. 1, pp. 157–163. https://doi.org/10.1136/ard.2010.131797Sekukinumab effcacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study / J. Sieper [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 76, N 3. – P. 571–592. https://doi.org/10.1136/annrheumdis-2016-210023Sieper J., Listing J., Poddubnyy D., Song I.-H., Hermann K.-G., Callhoff J., Syrbe U., Braun J., Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomized multicenter trial (ENRADAS). Annals of the Rheumatic Diseases, 2015, vol. 75, no. 8, pp. 1438–1443. https://doi.org/10.1136/annrheumdis-2015-207897Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective. Long-term, follow-up study / F. Cantini [et al.] // Biologics. – 2013. – Vol. 7. – P. 1–6. https://doi.org/10.2147/btt.s31474Cantini F., Laura N., Kaloudi C., Carlotta N. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective. Long-term, follow-up study. Biologics, 2013, vol. 7, pp. 1–6. https://doi.org/10.2147/btt.s31474Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis; 2 year data of the ESTHER trial / I. H. Song [et al.] // An. Rheum. Dis. – 2012. – Vol. 71, N 7. – P. 1212–1215. https://doi.org/10.1136/annrheumdis-2011-201010Song I. H., Althoff C. E., Haibel H., Hermann K.-G. A., Poddubnyy D., Listing J. [et al.]. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis; 2 year data of the ESTHER trial. Annals of the Rheumatic Diseases, 2012, vol. 71, no. 7, pp. 1212–1215. https://doi.org/10.1136/annrheumdis-2011-201010Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery / B. Vander Cruyssen [et al.] // Rheumatology (Oxford). – 2009. – Vol. 49, N 1. – P. 73–81. https://doi.org/10.1093/rheumatology/kep174Vander Cruyssen B., Muñoz-Gomariz E., Font P., Mulero J., de Vlam K., Boonen A., Vazquez-Mellado J., Flores D., Vastesaeger N., Collantes E. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford), 2009, vol. 49, no. 1, pp. 73–81. https://doi.org/10.1093/rheumatology/kep174van Royen, B. J. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structed review of three methods of treatment / van Royen B. J., de Gast A. // Ann. Rheum. Dis. – 1999. – Vol. 58, N 7. – P. 399–406. https://doi.org/10.1136/ard.58.7.399van Royen B. J., de Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structed review of three methods of treatment. Annals of the Rheumatic Diseases, 1999, vol. 58, no. 7, pp. 399–406. https://doi.org/10.1136/ard.58.7.399Westerveld, L. A. Spinal fractures in patients with ankylosing pinal disorders: a systematic review of the literature on treatment, neurological status and complications / L. A. Westerveld, J. J. Verlaan, F. C. Oner // Eur. Spine J. – 2008. – Vol. 18, N 2. – P. 145–156. https://doi.org/10.1007/s00586-008-0764-0Westerveld L. A., Verlaan J. J., Oner F. C. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. European Spine Journal, 2008, vol. 18, no. 2, pp. 145–156. https://doi.org/10.1007/s00586-008-0764-0

The authors declare that there are no conflicts of interest present.